 BEIJING, Nov. 09, 2020 GLOBE NEWSWIRE -- Genetron Holdings Limited Genetron Health or the Company, NASDAQ:GTH, a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited financial results for the third quarter ended September 30, 2020 and provided an update on recent developments. 